Loading...

Russell Pieper, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentNeurological Surgery
Address1450 3rd Street
San Francisco CA 94158
Phone415-502-7132
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Contributions of IDH1 mutation to alternative lengthening of telomeres in lower-grade glioma
    NIH/NINDS R01NS105087Sep 15, 2017 - May 31, 2022
    Role: Principal Investigator
    Understanding the role of altered metabolism in gliomagenesis
    NIH/NCI R01CA171610Feb 1, 2013 - Jan 31, 2018
    Role: Principal Investigator
    Training Program in Translational Brain Tumor Research
    NIH/NCI T32CA151022Sep 1, 2010 - Aug 31, 2020
    Role: Co-Principal Investigator
    A PTEN-regulated ubiquitin switch controlling TRAIL sensitivity in GBM
    NIH/NCI R01CA136774Jul 1, 2009 - Apr 30, 2014
    Role: Principal Investigator
    UNDERSTANDING TRAIL SENSITIVITY IN HUMAN GLIOMA
    NIH/NCI R01CA115638Jun 1, 2006 - Apr 30, 2012
    Role: Principal Investigator
    Imaging and Tissue Correlates to Optimize Management of Glioblastoma
    NIH/NCI P01CA118816Dec 1, 2005 - Jul 31, 2018
    Role: Co-Investigator
    P38, G2 Arrest, and Temozolomide Resistance in Gliomas
    NIH/NCI R01CA100011Feb 1, 2004 - Jan 31, 2010
    Role: Principal Investigator
    SPORE: Brain Tumore SPORE Grant
    NIH/NCI P50CA097257Sep 20, 2002 - Aug 31, 2018
    Role: Co-Investigator
    Contributions of Akt to Glioblastoma Formation
    NIH/NCI R01CA094989Apr 1, 2002 - Mar 31, 2007
    Role: Principal Investigator
    TRIGGERING OF ABERRANT CPG ISLAND METHYLATION
    NIH/NCI R01CA085352Jul 1, 2000 - Jun 30, 2003
    Role: Principal Investigator
    EXPRESSION AND SILENCING OF CPG ISLAND-CONTAINING GENES
    NIH/NCI R01CA079496Mar 1, 1999 - Feb 28, 2002
    Role: Principal Investigator
    CHROMATIN STRUCTURE AND CONTROL
    NIH/NCI R01CA055064Aug 1, 1997 - Jun 30, 2000
    Role: Principal Investigator
    ALKYLTRANSFERASE STRUCTURE AND FUNCTION
    NIH/NCI R01CA062389Jul 1, 1994 - Jun 30, 1998
    Role: Principal Investigator
    ALKYLTRANSFERASE EXPRESSION/DNA METHYLATION
    NIH/NCI R29CA055064Jul 1, 1991 - Jun 30, 1997
    Role: Principal Investigator
    CONSEQUENCES OF SELECTIVE INDUCTION OF DNA CROSSLINKS
    NIH/NCI F32CA008685Sep 22, 1990
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wood MD, Mukherjee J, Pieper R. Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro. Sci Rep. 2018 Apr 11; 8(1):5805. PMID: 29643433.
      View in: PubMed
    2. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper R, Phillips JJ, Ronen SM. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3. PMID: 29619216.
      View in: PubMed
    3. Mukherjee J, Johannessen TA, Ohba S, Chow TT, Jones LE, Pandita A, Pieper R. Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma. Cancer Res. 2018 Mar 15. PMID: 29545335.
      View in: PubMed
    4. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper R, Phillips JJ, Ronen SM. 2-hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas. Cancer Res. 2018 Jan 22. PMID: 29358170.
      View in: PubMed
    5. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper R. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689. PMID: 27758882.
      View in: PubMed
    6. Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper R. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 10; 14(10):976-983. PMID: 27430238.
      View in: PubMed
    7. Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper R, Ronen SM. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 07; 7(23):34942-55. PMID: 27144334.
      View in: PubMed
    8. Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper R. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. Int J Cancer. 2016 Jul 01; 139(1):99-111. PMID: 26874904.
      View in: PubMed
    9. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper R, Ronen SM. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 01; 75(15):2999-3009. PMID: 26045167; PMCID: PMC4526330.
    10. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper R, Phillips JJ, Ronen SM. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10(2):e0118781. PMID: 25706986; PMCID: PMC4338038.
    11. Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ, Pieper R. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 2014 Dec 01; 74(23):7115-24. PMID: 25320009; PMCID: PMC4253720.
    12. Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper R, Phillips JJ, Ronen SM. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase. PLoS One. 2014; 9(9):e108289. PMID: 25243911; PMCID: PMC4171511.
    13. Ohba S, Mukherjee J, See WL, Pieper R. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. 2014 Sep 01; 74(17):4836-44. PMID: 25035396; PMCID: PMC4154998.
    14. Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, Pieper R, Phillips JJ, Ronen SM. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. Cancer Res. 2014 Aug 15; 74(16):4247-57. PMID: 24876103; PMCID: PMC4134724.
    15. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper R, Ronen SM, Weiss S, Luchman HA, Cairncross JG. Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol. 2014 May; 16(5):686-95. PMID: 24366912; PMCID: PMC3984548.
    16. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper R. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One. 2013; 8(5):e62351. PMID: 23667469; PMCID: PMC3646831.
    17. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper R. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013; 8(2):e57610. PMID: 23451252; PMCID: PMC3581484.
    18. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper R, Phillips JJ, Ronen SM. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Commun. 2013; 4:2429. PMID: 24019001; PMCID: PMC3908661.
    19. Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper R, Ronen SM, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul; 70(1):33-9. PMID: 22851374; PMCID: PMC3630274.
    20. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper R, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro Oncol. 2012 Aug; 14(8):1050-61. PMID: 22670012; PMCID: PMC3408258.
    21. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper R. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 2012 Jul 01; 72(13):3350-9. PMID: 22573716; PMCID: PMC4128256.
    22. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8. PMID: 21896554; PMCID: PMC3223090.
    23. Moreira F, Kiehl TR, So K, Ajeawung NF, Honculada C, Gould P, Pieper R, Kamnasaran D. NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas. Am J Pathol. 2011 Jul; 179(1):462-76. PMID: 21703424; PMCID: PMC3123785.
    24. Wang D, Olman MA, Stewart J, Tipps R, Huang P, Sanders PW, Toline E, Prayson RA, Lee J, Weil RJ, Palmer CA, Gillespie GY, Liu WM, Pieper R, Guan JL, Gladson CL. Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activity. PLoS One. 2011; 6(5):e19629. PMID: 21602932; PMCID: PMC3094350.
    25. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper R, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 2011 Jan 01; 71(1):106-15. PMID: 21199799; PMCID: PMC3077533.
    26. Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper R, Parsa AT. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neurosci. 2010 Dec; 17(12):1543-7. PMID: 20822910; PMCID: PMC3795509.
    27. Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, Pieper R. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2010 Jun 15; 70(12):5046-53. PMID: 20484045; PMCID: PMC2891229.
    28. Dai B, Pieper R, Li D, Wei P, Liu M, Woo SY, Aldape KD, Sawaya R, Xie K, Huang S. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res. 2010 Apr 01; 70(7):2951-61. PMID: 20332230; PMCID: PMC2848915.
    29. Han SJ, Ahn BJ, Waldron JS, Yang I, Fang S, Crane CA, Pieper R, Parsa AT. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport. 2009 Dec 09; 20(18):1597-602. PMID: 19875977; PMCID: PMC3666317.
    30. Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper R. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res. 2009 Oct 15; 69(20):7911-6. PMID: 19808964; PMCID: PMC3229302.
    31. Crane C, Panner A, Pieper R, Arbiser J, Parsa AT. Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother. 2009 Jul-Aug; 32(6):585-92. PMID: 19483651; PMCID: PMC3795513.
    32. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper R, Habib AA. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009 Apr 01; 69(7):2809-16. PMID: 19339267; PMCID: PMC2859885.
    33. Dinca EB, Lu KV, Sarkaria JN, Pieper R, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res. 2008 Dec 15; 68(24):10034-9. PMID: 19074867; PMCID: PMC2987557.
    34. Nakamura JL, Garcia E, Pieper R. S6K1 plays a key role in glial transformation. Cancer Res. 2008 Aug 15; 68(16):6516-23. PMID: 18701474; PMCID: PMC2538583.
    35. Zhao Y, Xiao A, Dipierro CG, Abdel-Fattah R, Amos S, Redpath GT, Carpenter JE, Pieper R, Hussaini IM. H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia. 2008 Jun; 56(8):917-24. PMID: 18383343; PMCID: PMC2408768.
    36. Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper R, Lal A. Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia. 2008 Jun; 10(6):604-12. PMID: 18516297; PMCID: PMC2386545.
    37. Chi JH, Panner A, Cachola K, Crane CA, Murray J, Pieper R, James CD, Parsa AT. Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation. J Neurosurg. 2008 Feb; 108(2):299-303. PMID: 18240926.
      View in: PubMed
    38. Nakamura JL, Haas-Kogan DA, Pieper R. Glioma invasiveness responds variably to irradiation in a co-culture model. Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):880-6. PMID: 17889268.
      View in: PubMed
    39. Panner A, Murray JC, Berger MS, Pieper R. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res. 2007 Oct 01; 67(19):9482-9. PMID: 17909058.
      View in: PubMed
    40. Cobbs CS, Soroceanu L, Denham S, Zhang W, Britt WJ, Pieper R, Kraus MH. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol. 2007 Dec; 85(3):271-80. PMID: 17589804.
      View in: PubMed
    41. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper R. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007 Mar; 106(3):417-27. PMID: 17367064.
      View in: PubMed
    42. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper R. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007 Jan; 13(1):84-8. PMID: 17159987.
      View in: PubMed
    43. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper R. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 2006 Dec 01; 66(23):11331-40. PMID: 17145879.
      View in: PubMed
    44. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper R, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485. PMID: 17177598; PMCID: PMC1702556.
    45. Mirzoeva OK, Kawaguchi T, Pieper R. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol Cancer Ther. 2006 Nov; 5(11):2757-66. PMID: 17121922.
      View in: PubMed
    46. Kanamori M, Kawaguchi T, Berger MS, Pieper R. Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis. J Biol Chem. 2006 Dec 01; 281(48):37256-64. PMID: 17028191.
      View in: PubMed
    47. Panner A, Parsa AT, Pieper R. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1313-22. PMID: 17020463.
      View in: PubMed
    48. Panner A, Nakamura JL, Parsa AT, Rodriguez-Viciana P, Berger MS, Stokoe D, Pieper R. mTOR-independent translational control of the extrinsic cell death pathway by RalA. Mol Cell Biol. 2006 Oct; 26(20):7345-57. PMID: 16894031; PMCID: PMC1636864.
    49. Panner A, Parsa AT, Pieper R. Translational regulation of TRAIL sensitivity. Cell Cycle. 2006 Jan; 5(2):147-50. PMID: 16397410.
      View in: PubMed
    50. Panner A, James CD, Berger MS, Pieper R. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005 Oct; 25(20):8809-23. PMID: 16199861; PMCID: PMC1265779.
    51. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper R. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 2005 Jun 01; 65(11):4861-9. PMID: 15930307.
      View in: PubMed
    52. Rong Y, Post DE, Pieper R, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 2005 Feb 15; 65(4):1406-13. PMID: 15735028.
      View in: PubMed
    53. Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper R, Stokoe D, Haas-Kogan DA. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol. 2005 Feb; 71(3):215-22. PMID: 15735908.
      View in: PubMed
    54. Saito R, Bringas JR, Panner A, Tamas M, Pieper R, Berger MS, Bankiewicz KS. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004 Oct 01; 64(19):6858-62. PMID: 15466173.
      View in: PubMed
    55. Hirose Y, Katayama M, Berger MS, Pieper R. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg. 2004 Jun; 100(6):1060-5. PMID: 15200121.
      View in: PubMed
    56. Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper R. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res. 2004 Apr 15; 64(8):2751-8. PMID: 15087390.
      View in: PubMed
    57. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper R. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003 Nov; 23(22):8306-15. PMID: 14585987; PMCID: PMC262371.
    58. Sonoda Y, Kanamori M, Deen DF, Cheng SY, Berger MS, Pieper R. Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. Cancer Res. 2003 Apr 15; 63(8):1962-8. PMID: 12702589.
      View in: PubMed
    59. Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper R. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg. 2003 Mar; 98(3):591-8. PMID: 12650433.
      View in: PubMed
    60. Pieper R. Defined human cellular systems in the study of glioma development. Front Biosci. 2003 Jan 01; 8:s19-27. PMID: 12456369.
      View in: PubMed